Tag: NOVEL

  • Afobazole

    Selective non-benzodiazepine anxiolytic with sigma-1 receptor chaperone agonism and multi-target neuroprotective activity

    A 2-mercaptobenzimidazole derivative developed at the V.V. Zakusov Research Institute of Pharmacology and registered in Russia as a non-sedating anxiolytic, distinguished from benzodiazepines by absence of dependence liability and from buspirone by sigma-1 receptor chaperone agonism as the principal molecular mechanism.

    Abstract

    Afobazole (INN fabomotizole; development code CM-346; CAS 173352-21-1) is a 2-mercaptobenzimidazole anxiolytic synthesized and pharmacologically characterized at the V.V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences under the direction of Academician S.B. Seredenin. The compound was registered in the Russian Federation in 2006 for the treatment of generalized anxiety disorder and adjustment disorders, and was assigned the International Nonproprietary Name fabomotizole by the World Health Organization in 2012. Structurally, afobazole is 5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole, a synthetic benzimidazole bearing a thioether-linked morpholine side chain and an ethoxy substituent on the aromatic ring. The molecular formula is C15H21N3O2S (free base, molecular weight 307.41 g/mol), and the compound is supplied pharmaceutically as the dihydrochloride salt (C15H23Cl2N3O2S, molecular weight 380.33 g/mol).

    The pharmacological profile of afobazole is multi-target. Radioligand binding studies have identified the sigma-1 receptor chaperone protein (Sigma1R; Ki approximately 5.9 micromolar), NRH:quinone reductase 2 (NQO2, also designated the MT3 melatonin binding site; Ki approximately 0.97 micromolar), monoamine oxidase A (MAO-A regulatory site; Ki approximately 3.6 micromolar), and the melatonin MT1 receptor (Ki approximately 16 micromolar) as the principal molecular targets [1, 2]. The sigma-1 receptor interaction is the best-characterized mechanism: afobazole acts as a Sigma1R agonist, promoting dissociation of the Sigma1R-BiP complex at the endoplasmic reticulum membrane and downstream modulation of calcium signaling, inositol 1,4,5-trisphosphate receptor function, and expression of neurotrophic factors including nerve growth factor and brain-derived neurotrophic factor [3, 4]. The anxiolytic effect is blocked by selective Sigma1R antagonists (BD-1047, NE-100) in rodent behavioral models, confirming the dependence of the therapeutic activity on Sigma1R engagement [5, 6].

    Pharmacokinetics are characterized by rapid oral absorption (Tmax approximately 0.85 hours), pronounced first-pass hepatic metabolism (oral bioavailability approximately 44 percent), and a short plasma elimination half-life (approximately 0.82 hours) [9]. Despite the short systemic half-life, the anxiolytic effect persists substantially beyond the plasma residence of the parent compound, a pharmacodynamic feature attributed to the slow dissociation kinetics of the Sigma1R chaperone complex and to the sustained expression of downstream neurotrophic mediators.

    The clinical evidence base comprises several Russian multicenter trials. The principal registration study was a randomized, double-blind, active-controlled trial of 150 patients with generalized anxiety disorder or adjustment disorders comparing afobazole (30 mg/day) to diazepam (30 mg/day) for 30 days; afobazole produced greater reduction in Hamilton Anxiety Rating Scale total score than diazepam (mean difference 2.93 points; p = 0.01), with 15 adverse events in the afobazole group versus 199 in the diazepam group, and no withdrawal syndrome on discontinuation [8]. Additional studies have evaluated afobazole in somatoform disorders, irritable bowel syndrome, premenstrual syndrome, alcohol withdrawal, and tobacco cessation, with consistent evidence of anxiolytic efficacy and favorable tolerability [10, 11, 12].

    Preclinical research has extended the pharmacological profile well beyond anxiolysis. Afobazole produces Sigma1R-dependent neuroprotection in rat models of ischemic stroke (middle cerebral artery occlusion), with reduced infarct volume and improved neurological outcomes when administered up to 24 hours post-occlusion [13, 14]. In the 6-hydroxydopamine mouse model of Parkinson’s disease, afobazole at 2.5 mg/kg intraperitoneally for 14 days restored striatal dopamine content, preserved tyrosine hydroxylase-positive neurons in the substantia nigra, and normalized motor coordination; these effects were abolished by the Sigma1R antagonist BD-1047 [15, 16]. Cardioprotective activity has been demonstrated in models of isoproterenol-induced myocardial injury, chronic heart failure, and alcoholic cardiomyopathy, with attenuation of pathological remodeling, preserved inotropic function, and reduced brain natriuretic peptide levels [17, 18, 19]. Angiogenic effects have also been reported [20].

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • CDD-0102

    Selective M1 muscarinic acetylcholine receptor partial agonist of the tetrahydropyrimidine-oxadiazole structural class

    A functionally selective partial agonist at the M1 muscarinic acetylcholine receptor developed at the University of Toledo as a cognitive enhancer and neuroprotective agent for Alzheimer’s disease, distinguished from earlier muscarinic agonists by subtype selectivity, low cholinergic adverse-event burden, and oral bioavailability.

    Abstract

    CDD-0102, the hydrochloride salt of 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine (designated CDD-0102A in its salt form), is a functionally selective partial agonist at the M1 subtype of the muscarinic acetylcholine receptor developed at the University of Toledo College of Pharmacy under the direction of W.S. Messer Jr. as a candidate therapeutic for Alzheimer’s disease and related cognitive disorders. The compound occupies the orthosteric acetylcholine-binding site of the M1 receptor with partial agonist intrinsic activity sufficient to activate phospholipase C-coupled signaling, stimulate non-amyloidogenic processing of amyloid precursor protein (APP) through alpha-secretase, and enhance cognitive function in rodent models of cholinergic deficit, while exhibiting minimal functional activity at M2, M4, and M5 muscarinic subtypes and only weak activity at M3 receptors. This functional selectivity profile distinguishes CDD-0102 from the first-generation M1-preferring muscarinic agonists (xanomeline, sabcomeline, talsaclidine, cevimeline) that produced dose-limiting cholinergic adverse events (salivation, gastrointestinal disturbance, diaphoresis) attributable to activation of peripheral M2 and M3 receptors, a limitation that terminated or constrained the clinical development of each of those compounds in the Alzheimer’s indication. The pharmacological characterization of CDD-0102 encompasses M1-selective receptor binding, stimulation of soluble APP-alpha (sAPPalpha) secretion from Chinese hamster ovary cells stably expressing human M1 receptors, neuroprotective activity in cell culture, brain penetration following systemic administration in rodents, oral bioavailability, and a favorable acute toxicity profile. More recent preclinical work has extended the pharmacological profile to autism spectrum disorder models, demonstrating that CDD-0102A attenuates stereotyped motor behaviors (self-grooming, digging) and modulates glutamate efflux in dorsolateral striatum of the BTBR T+ Itpr3tf/J mouse, a model of autism-relevant repetitive behavior and social deficit. The compound advanced through preclinical development with support from the National Center for Advancing Translational Sciences (NCATS) Bridging Interventional Development Gaps (BrIDGs) program, which funded the IND-enabling studies including synthetic scale-up, formulation, pharmacokinetics, and toxicology. An Investigational New Drug (IND) application was filed with the United States Food and Drug Administration, and Phase 1 clinical testing was initiated. Published results from Phase 1 clinical evaluation have not appeared in the peer-reviewed literature as of the most recent monograph revision. The compound is not registered as a marketed medicine in any jurisdiction. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • 7,8-Dihydroxyflavone

    Naturally occurring flavone and selective small-molecule tropomyosin receptor kinase B (TrkB) agonist with BDNF-mimetic neurotrophic activity

    A naturally occurring dihydroxylated flavone identified through cell-based TrkB receptor screening as the first orally bioactive small-molecule brain-derived neurotrophic factor mimetic, distinguished by selective TrkB agonism, blood-brain barrier penetration, and broad preclinical neuroprotective and procognitive efficacy across neurodegenerative, neuropsychiatric, and metabolic disease models.

    Abstract

    7,8-Dihydroxyflavone (7,8-DHF), also designated tropoflavin, is a naturally occurring flavone first isolated from the leaves of Godmania aesculifolia and subsequently identified in Tridax procumbens, Primula vulgaris, and other plant species. The compound was characterized in 2010 by Jang et al. at Emory University as the first orally bioactive, blood-brain-barrier-penetrant small-molecule agonist of the tropomyosin receptor kinase B (TrkB), the principal high-affinity signaling receptor for brain-derived neurotrophic factor (BDNF) [1]. 7,8-DHF binds the extracellular domain of TrkB with a dissociation constant of approximately 320 nM by filter binding assay and approximately 15.4 nM by surface plasmon resonance, triggering receptor dimerization, autophosphorylation at tyrosine residues 706/707, and activation of the downstream PI3K/Akt and MAPK/ERK signaling cascades that mediate neuronal survival, synaptic plasticity, and long-term potentiation [1, 2]. The compound displays selectivity for TrkB over the related neurotrophin receptors TrkA and TrkC and does not activate TrkB kinase-dead mutants, confirming that the phosphorylation signal arises from the receptor itself rather than from off-target tyrosine kinases [2].

    Pharmacokinetic characterization in rodents reveals oral bioavailability of approximately 4.6 percent, a plasma half-life of approximately 134 minutes, rapid brain penetration with peak brain concentrations at 10 minutes after oral dosing, and primary hepatic metabolism through glucuronidation, sulfation, and catechol-O-methyltransferase-mediated methylation [3, 4]. The O-methylated metabolites (7-methoxy-8-hydroxyflavone and 7-hydroxy-8-methoxyflavone) retain TrkB agonist activity in vitro and in vivo, extending the effective pharmacodynamic window beyond the parent compound [5]. The modest oral bioavailability prompted the development of the prodrug R13 (a carbamate ester derivative) by the Ye laboratory, which increases oral bioavailability to approximately 10.5 percent and extends the plasma half-life to approximately 220 minutes [6]. R13 has entered Phase 1 clinical evaluation for Alzheimer’s disease, representing the most advanced clinical translation of TrkB agonist pharmacology from this scaffold.

    Preclinical pharmacology is extensive. In Parkinson’s disease models, the compound protects dopaminergic neurons from MPTP- and rotenone-induced degeneration and improves motor function [10]. In depression models, 7,8-DHF reverses learned helplessness, chronic mild stress, and social defeat stress phenotypes through restoration of hippocampal and prefrontal cortical TrkB-BDNF signaling [11, 12]. Additional preclinical efficacy has been demonstrated in models of Huntington’s disease, amyotrophic lateral sclerosis, traumatic brain injury, post-traumatic stress disorder, Rett syndrome, fragile X syndrome, retinal ganglion cell degeneration, and diet-induced obesity [13, 14, 15, 16, 17, 18, 19].

    A 7-month oral dosing study in a non-human primate model of Parkinson’s disease similarly reported no toxic reactions [20]. No human clinical trial data for the parent compound 7,8-DHF have been published; clinical development has proceeded through the prodrug R13. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • P7C3-A20

    Aminopropyl carbazole neuroprotective agent functioning as a nicotinamide phosphoribosyltransferase (NAMPT) positive allosteric modulator

    A synthetic 3,6-dibromocarbazole derivative discovered through target-agnostic in vivo neurogenesis screening, distinguished by its activation of the NAD+ salvage enzyme NAMPT and broad neuroprotective efficacy across preclinical models of traumatic brain injury, ischemic stroke, Parkinson disease, amyotrophic lateral sclerosis, and Alzheimer disease.

    Abstract

    P7C3-A20, the fluorinated and methoxylated analog of the parent aminopropyl carbazole P7C3, is a synthetic neuroprotective compound identified through iterative structure-activity optimization of a chemical series originally discovered in a target-agnostic in vivo screen for enhancers of adult hippocampal neurogenesis conducted by Pieper, McKnight, and colleagues at the University of Texas Southwestern Medical Center [1]. The parent compound P7C3 was one of eight hits from a library of approximately 1,000 small molecules screened for their ability to augment the survival of newborn neurons in the subgranular zone of the murine dentate gyrus. Subsequent medicinal chemistry optimization, principally the replacement of the central hydroxyl with fluorine and the introduction of a methoxy substituent on the aniline ring, yielded P7C3-A20, which demonstrated approximately ten-fold greater proneurogenic potency than the parent compound while retaining favorable oral bioavailability, blood-brain barrier penetration, and tolerability in chronic dosing studies in rodents and nonhuman primates [2, 3]. The molecular target of P7C3-A20 was identified by Wang et al. (2014) as nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the nicotinamide adenine dinucleotide (NAD+) salvage pathway [4]. P7C3-A20 functions as a positive allosteric modulator of NAMPT, enhancing the conversion of nicotinamide to nicotinamide mononucleotide (NMN) and thereby augmenting intracellular NAD+ levels under conditions of metabolic stress without elevating NAD+ to supraphysiologic concentrations. This mechanism distinguishes P7C3-A20 from direct NAD+ precursor supplementation strategies (nicotinamide riboside, nicotinamide mononucleotide) by preserving endogenous feedback regulation of the salvage pathway. The downstream consequences of NAMPT activation and NAD+ restoration include maintenance of sirtuin deacetylase activity (particularly SIRT1 and SIRT3), protection of mitochondrial bioenergetics, suppression of oxidative stress and DNA damage, attenuation of neuroinflammation through microglial modulation, and enhancement of the survival of newly generated neurons during adult hippocampal neurogenesis. The preclinical pharmacology of P7C3-A20 has been characterized across an unusually broad spectrum of neurodegenerative and neurotraumatic disease models. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson disease, P7C3-A20 substantially preserved dopaminergic neurons in the substantia nigra [5]. In the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS), P7C3-A20 reduced motor neuron cell death in the spinal cord [6]. In models of traumatic brain injury (TBI), P7C3-A20 blocked axonal degeneration and preserved neurological function when administered acutely [7], and, in a landmark 2020 study, restored blood-brain barrier integrity, arrested chronic neurodegeneration, and recovered normal cognitive function when treatment was initiated a full twelve months after the initial injury [8]. In rat models of focal ischemic stroke, P7C3-A20 promoted post-ischemic neurogenesis, restored cortical NAD+ levels, and improved chronic sensorimotor and cognitive outcomes [9]. In retinal degeneration models, the P7C3 class protected retinal ganglion cells from optic nerve injury [10]. In 2025, Vazquez-Rosa et al. published a study in Cell Reports Medicine demonstrating that P7C3-A20 treatment of 5xFAD and PS19 transgenic mice with advanced Alzheimer-like pathology produced comprehensive reversal of tau phosphorylation, blood-brain barrier deterioration, oxidative stress, DNA damage, and neuroinflammation, with full cognitive recovery and normalization of the clinical biomarker p-tau217 [11]. P7C3-A20 has not entered human clinical trials as of the most recent monograph revision. The compound is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from multiple chemical suppliers at high purity. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • MitoQ

    Mitochondria-targeted ubiquinone-derived antioxidant conjugated to a triphenylphosphonium cation

    A synthetic coenzyme Q10 analog covalently linked to a lipophilic triphenylphosphonium moiety that drives selective mitochondrial accumulation, enabling targeted quenching of reactive oxygen species at the inner mitochondrial membrane with demonstrated vascular, hepatoprotective, and anti-inflammatory activity in human clinical studies.

    Abstract

    Mitoquinone mesylate (MitoQ) is a mitochondria-targeted antioxidant composed of a ubiquinone moiety covalently linked via a ten-carbon alkyl chain to a triphenylphosphonium (TPP+) cation, enabling rapid permeation of lipid bilayers and accumulation within the mitochondrial matrix at concentrations up to several hundred-fold above extracellular levels, driven by the large negative mitochondrial membrane potential (approximately negative 150 to negative 180 millivolts). The compound was developed in the 1990s by Robin Smith and Michael Murphy at the University of Otago, New Zealand, as an approach to overcoming the failure of conventional untargeted antioxidants (including native coenzyme Q10) to achieve therapeutically meaningful concentrations within mitochondria, the principal intracellular source of reactive oxygen species (ROS). Within the mitochondrion, MitoQ adsorbs to the matrix-facing leaflet of the inner mitochondrial membrane, where the ubiquinone head group is reduced to the active antioxidant ubiquinol form by complex II (succinate:ubiquinone oxidoreductase) of the electron transport chain. The ubiquinol form scavenges superoxide, hydroxyl radicals, and peroxyl radicals, preventing lipid peroxidation of cardiolipin and other mitochondrial membrane phospholipids. Following oxidation during radical quenching, the resulting ubiquinone is re-reduced by complex II, establishing a catalytic antioxidant cycle that permits repeated radical neutralization from a single molecule. This recycling mechanism distinguishes MitoQ from stoichiometric antioxidants such as alpha-tocopherol that are consumed in the quenching reaction. Preclinical pharmacology has demonstrated protective effects in rodent models of ischemia-reperfusion injury, diabetic nephropathy, nonalcoholic fatty liver disease, sepsis-associated organ failure, pulmonary hypertension, Alzheimer’s disease, doxorubicin-induced cardiomyopathy, cisplatin nephrotoxicity, and metabolic syndrome, with consistent reductions in mitochondrial oxidative damage markers, preservation of mitochondrial membrane potential, and attenuation of downstream inflammatory signaling through suppression of NF-kappaB activation and NLRP3 inflammasome assembly. Four completed human clinical trials define the current clinical evidence base. A 2024 exploratory pilot trial (Jain et al. 2024) of MitoQ as post-exposure prophylaxis against SARS-CoV-2 infection reported reduced infection rates and symptom duration in the treatment group versus matched controls. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • SRT2104

    Selective small-molecule allosteric activator of NAD-dependent protein deacetylase sirtuin 1 (SIRT1)

    A second-generation imidazothiazole-scaffold sirtuin 1 activator developed by Sirtris Pharmaceuticals and advanced through multiple Phase 2 clinical programs by GlaxoSmithKline, distinguished from first-generation sirtuin-activating compounds by high target selectivity and favorable oral pharmacokinetics.

    Abstract

    SRT2104 (GSK2245840) is a synthetic, orally bioavailable, small-molecule allosteric activator of the NAD-dependent protein deacetylase sirtuin 1 (SIRT1, silent mating type information regulation 2 homolog 1), developed at Sirtris Pharmaceuticals and subsequently advanced into clinical trials by GlaxoSmithKline following the 2008 acquisition of Sirtris for approximately 720 million United States dollars. The compound is a second-generation sirtuin-activating compound (STAC) built on an optimized imidazo[2,1-b]thiazole scaffold and is reported to activate SIRT1 deacetylase activity approximately 1000-fold more potently than the natural polyphenol resveratrol in fluorophore-tagged peptide substrate assays, with minimal activity against a panel of more than 180 non-SIRT1 targets including kinases, G-protein-coupled receptors, nuclear receptors, ion channels, enzymes, and transporters [1, 2]. The allosteric mechanism involves binding to the N-terminal domain of SIRT1, lowering the Michaelis constant (Km) for the acetylated protein substrate without competing with either the NAD cofactor or the substrate acetyl-lysine site [3]. Downstream consequences of SIRT1 activation by SRT2104 include deacetylation and functional modulation of the transcription factor p53, the RelA/p65 subunit of nuclear factor kappa B (NF-kB), forkhead box protein O3 (FOXO3), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), and signal transducer and activator of transcription 3 (STAT3), producing composite anti-inflammatory, metabolic, and cytoprotective effects that have been characterized across a broad range of preclinical disease models [4, 5].

    The variable and non-dose-proportional pharmacokinetic profile has been identified as a principal limitation of the compound for clinical development in its current oral formulation. SRT2104 is poorly soluble in water and is formulated as a lipid-based oral capsule to improve bioavailability.

    Clinical evaluation has spanned at least seven registered clinical trials across multiple indications. A separate cardiometabolic study in type 2 diabetic subjects reported trends toward improved endothelial function and arterial stiffness [9]. In a human endotoxemia model, SRT2104 pretreatment significantly reduced lipopolysaccharide-induced cytokine release (interleukin-6, interleukin-8) and coagulation activation, representing the first human demonstration of anti-inflammatory and anticoagulant activity consistent with pharmacological SIRT1 activation [12].

    Preclinical pharmacology is extensive. The Mercken et al. (2014) study at the National Institute on Aging demonstrated that SRT2104 extends both mean and maximum lifespan of male mice fed a standard diet by 9.7 percent and 4.9 percent respectively, with preserved bone mineral density, muscle mass, motor coordination, and insulin sensitivity [13]. The Jiang et al. (2014) study demonstrated blood-brain barrier penetration, attenuation of brain atrophy, improvement of motor function, and extension of median lifespan by approximately 16 percent in N171-82Q Huntington disease model mice [14]. Additional preclinical evidence spans emphysema, sepsis, neonatal white matter injury, microglia polarization, dendritic outgrowth, and auditory cell senescence. GlaxoSmithKline discontinued active clinical development of SRT2104 following the 2013 closure of the Sirtris unit, though the compound remains widely used as a reference SIRT1 activator in academic and preclinical research. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Noopept

    Synthetic dipeptide nootropic and neuroprotectant derived from cycloprolylglycine with AMPA receptor positive allosteric modulation and neurotrophic factor upregulation

    A proline-glycine dipeptide cognitive enhancer (GVS-111) developed at the Zakusov Institute of Pharmacology in Russia, distinguished from classical racetam nootropics by approximately 1000-fold greater mass potency, rapid conversion to the endogenous neuropeptide cycloprolylglycine, and a multifactorial mechanism encompassing AMPA receptor positive allosteric modulation, NMDA receptor modulation, NGF and BDNF upregulation, HIF-1 transcription factor activation, and neuroprotection against amyloid-beta toxicity and tau hyperphosphorylation.

    Abstract

    Noopept (INN: omberacetam; development code GVS-111; N-phenylacetyl-L-prolylglycine ethyl ester; CAS 157115-85-0; molecular formula C17H22N2O4; molecular weight 318.37 g/mol) is a synthetic dipeptide nootropic and neuroprotectant developed in the mid-1990s at the V.V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences by Tatyana Gudasheva, Rita Ostrovskaya, and Sergei Seredenin using a drug-based peptide design strategy that models the pyrrolidone ring of piracetam as the central element of a beta-turn dipeptide. Noopept is not approved by the United States Food and Drug Administration, the European Medicines Agency, or the regulatory authorities of Japan, Australia, or Canada. It is sold internationally as a research-grade compound and as an unregulated dietary supplement in several jurisdictions.

    The pharmacological mechanism of noopept is multifactorial and operates through both the parent compound and its principal active metabolite, cycloprolylglycine (cyclo-L-prolylglycine, CPG), an endogenous brain dipeptide. The parent compound and CPG function as positive allosteric modulators of AMPA-subtype ionotropic glutamate receptors, increasing glutamate sensitivity without direct agonist binding. Noopept modulates NMDA receptor expression and function, upregulates the expression of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in hippocampal and cortical neurons on chronic administration, activates the transcription factor hypoxia-inducible factor 1 (HIF-1) through inhibition of prolyl hydroxylase, and provides direct neuroprotection against amyloid-beta peptide toxicity, glutamate excitotoxicity, oxidative stress, and calcium overload in cellular and animal models. In Alzheimer’s disease cellular models, noopept attenuates tau hyperphosphorylation at Ser396 and reduces apoptosis through suppression of the mitochondrial apoptotic pathway.

    Pharmacokinetics in humans are characterized by rapid oral absorption (time to peak plasma concentration approximately 15 to 20 minutes), extensive first-pass metabolism yielding an oral bioavailability of approximately 10 percent relative to parenteral administration, rapid hydrolysis of the parent ester to the active metabolite cycloprolylglycine, and a short plasma half-life of the parent compound. The pharmacological effect persists for 3 to 6 hours after oral dosing, substantially longer than the plasma residence of the parent compound, consistent with the contribution of the longer-lived CPG metabolite and downstream transcriptional effects on neurotrophic factor expression. The compound does not appear to undergo significant cytochrome P450-mediated metabolism; the principal biotransformation is peptidase-mediated ester hydrolysis and amide cleavage.

    The clinical evidence base is concentrated in Russian-language literature and is modest by Western regulatory standards. Preclinical evidence is more extensive, spanning rodent models of ischemic brain injury, Alzheimer’s disease (both amyloid-beta infusion and transgenic models), traumatic brain injury, and age-related cognitive decline. Long-term safety data beyond 56 days of continuous administration are not available.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Larazotide

    Zonulin antagonist octapeptide and tight junction modulator

    An eight-residue zonulin receptor antagonist developed by Innovate Biopharmaceuticals (now 9 Meters Biopharma) as the first specific gut tight junction modulator advanced to Phase 3 in celiac disease.

    Abstract

    Larazotide acetate (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly; CAS 258818-34-7; molecular weight 754.86 free peptide) is an eight-residue synthetic peptide developed at the University of Maryland by Alessio Fasano and colleagues as a competitive antagonist at the zonulin receptor. Zonulin (also designated pre-haptoglobin 2) is the human ortholog of the Vibrio cholerae zonula occludens toxin (ZOT) and is the only known endogenous regulator of intestinal epithelial tight junction permeability; activation of the zonulin pathway in response to gluten exposure or other triggers produces transient opening of intestinal tight junctions and translocation of luminal antigens into the lamina propria, contributing to celiac disease pathogenesis and a broader leaky-gut phenotype implicated in autoimmune and inflammatory conditions. Larazotide binds the zonulin receptor and blocks ZOT/zonulin-induced tight junction disassembly without directly affecting baseline tight junction integrity. The compound was advanced through Phase 1 and Phase 2 trials in celiac disease and entered Phase 3 (CeDLara) for the residual gluten-cross-contamination phenotype in patients on a gluten-free diet who continue to experience symptoms. The Phase 3 readout in 2022 did not meet the primary endpoint of celiac disease patient-reported outcome, and 9 Meters Biopharma announced discontinuation of the program. Despite the clinical setback in celiac disease, larazotide remains a pharmacologically distinct research tool for tight junction modulation in inflammatory bowel disease, multiple sclerosis, and other indications where intestinal barrier dysfunction is implicated. Oral bioavailability is essentially zero (the peptide acts in the gut lumen and is not absorbed); the route of administration is per oral as a sustained-release formulation. Adverse events in clinical trials were mild and dominated by gastrointestinal effects.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Crystagen

    Synthetic immunomodulatory tripeptide bioregulator of thymic origin with epigenetic gene-regulatory and cytoprotective activity

    A synthetic tripeptide (L-Glu-L-Asp-L-Pro; EDP) derived from structural analysis of the thymic polypeptide complex Thymalin, developed at the Saint Petersburg Institute of Bioregulation and Gerontology as an ultrashort peptide bioregulator with immunomodulatory, cytoprotective, and epigenetic chromatin-regulatory activity targeting thymic epithelial cells, T-lymphocyte subpopulations, and heat-shock protein gene expression.

    Abstract

    Crystagen (L-glutamyl-L-aspartyl-L-proline; EDP tripeptide; molecular formula C14H21N3O8; molecular weight 359.33 g/mol) is a synthetic tripeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as one of the principal short-peptide bioactive components of Thymalin, a bovine thymus polypeptide extract approved in the Soviet Union and Russian Federation since 1982 for clinical immunocorrection [1, 2]. The compound belongs to the Khavinson class of ultrashort (two to seven residue) peptide bioregulators, a family of synthetic sequences modeled on tissue-specific peptide fragments isolated from organ extracts by acid-pepsin hydrolysis and ultrafiltration, and is designated as the thymic immune system bioregulator within this peptide family. Crystagen shares the Glu-Asp dipeptide core with the bronchial bioregulator Chonluten (Glu-Asp-Gly) and the cortical bioregulator Cortagen (Ala-Glu-Asp-Pro), differing from these compounds by the third-position proline residue and the absence of the N-terminal alanine extension, respectively; the single amino acid substitution at the third position determines tissue specificity within the Khavinson classification [3, 4]. In the Khavinson laboratory internal code system, the compound is designated T-36 [5]. The principal molecular mechanism of Crystagen, characterized through molecular modeling, cell culture, and organotypic tissue studies, is epigenetic regulation of gene expression through direct interaction of the tripeptide with double-stranded DNA in gene promoter regions and with histone proteins (H1, H2B, H3, H4), producing chromatin decondensation and reactivation of age-repressed transcriptional programs in immune cells [6, 7, 8]. The immunomodulatory activity, characterized in thymic cell cultures, splenic organotypic cultures, and in the THP-1 monocyte/macrophage cell line, includes stimulation of T-lymphocyte differentiation with increased CD3+ and CD4+ cell populations, normalization of the CD4+/CD8+ ratio, activation of B-cell immunity in the spleen, suppression of thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, enhancement of normal lymphocyte proliferation with concurrent inhibition of K-562 tumor cell proliferation, and modulation of cytokine expression including interleukin-6 normalization [9, 10, 11, 12]. The cytoprotective profile includes a pronounced upregulation of heat-shock protein gene HSPA1A (encoding HSP-70), with expression increasing approximately 2.2-fold relative to baseline in a study of highly trained female artistic gymnasts receiving Crystagen in combination with other peptide bioregulators, an effect accompanied by reduced incidence of acute respiratory infections during epidemic conditions [13, 14]. In a clinical observational study of elderly patients, oral Crystagen administration normalized immunogram parameters in 82 percent of treated individuals compared to 56 percent in the control group [15]. The geroprotective context for Crystagen derives from the parent compound Thymalin, which in a 266-patient, 6-to-8-year prospective clinical study conducted at the Saint Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences produced a 2.0-to-2.1-fold reduction in mortality rate relative to control, and a 4.1-fold mortality reduction when combined with the pineal peptide Epithalamin [16]. No formal pharmacokinetic studies have been published for Crystagen as the isolated synthetic EDP tripeptide. As a linear tripeptide with unprotected termini, the compound is expected to undergo rapid proteolytic degradation by aminopeptidases and carboxypeptidases in plasma and gastrointestinal fluid; however, molecular modeling studies have demonstrated that ultrashort peptides including EDP are substrates of the proton-coupled oligopeptide transporter (POT) family carriers PEPT1 and PEPT2, supporting intestinal absorption and cellular uptake through active transport mechanisms [17, 18]. The compound is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. It is not registered as a pharmaceutical product outside the Russian Federation. Crystagen is commercially available in Russia as a dietary supplement in capsule and sublingual formulations and is supplied internationally as a research-grade lyophilized peptide by multiple peptide synthesis vendors at greater than 95 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Pemvidutide

    Balanced dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist peptide with glycolipid half-life extension

    A 29-amino-acid unimolecular peptide engineered for equipotent GLP-1 and glucagon receptor co-agonism, conjugated to a proprietary glycolipid moiety for weekly subcutaneous dosing, under clinical development for metabolic dysfunction-associated steatohepatitis, obesity, and alcohol use disorder.

    Abstract

    Pemvidutide (ALT-801; CAS 2538014-94-5; UNII A35F525WBG; molecular formula C182H275N39O54; molecular weight 3873.42 g/mol) is a synthetic 29-amino-acid peptide that functions as a balanced (1:1) dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), developed by Altimmune, Inc. (Gaithersburg, Maryland) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The compound incorporates sequence elements derived from both GLP-1 and glucagon and is conjugated to an 18-carbon diacid alkyl chain through a proprietary glycosidic linkage (designated EuPort), which provides near-quantitative but transient binding to serum albumin and extends the plasma half-life to a duration consistent with once-weekly subcutaneous administration without dose titration [1, 2]. The dual receptor mechanism differentiates pemvidutide from selective GLP-1 receptor agonists such as semaglutide and liraglutide: GLP-1R activation suppresses appetite through hypothalamic and brainstem satiety circuits, delays gastric emptying, and improves glycemic control, while GCGR activation directly stimulates hepatic fatty acid beta-oxidation, suppresses de novo lipogenesis, and increases energy expenditure through thermogenic pathways, producing a composite antisteatotic and weight-reducing pharmacology that is mechanistically suited to liver-predominant metabolic disease [3, 4, 5]. In the translational AMLN diet-induced obese mouse model of NASH, pemvidutide at 10 nmol/kg subcutaneous produced approximately 25 percent body weight reduction, significant reductions in liver triglycerides, galectin-3, collagen type 1 alpha 1, and NAFLD Activity Score, with efficacy exceeding that of semaglutide and elafibranor at equimolar doses on composite histological endpoints [6]. Clinical development has advanced through Phase 1 studies (NCT04561245, 100 subjects), Phase 1b/2a studies in MASLD (NCT05006885, 95 subjects; NCT05292911, 64 subjects), the Phase 2 MOMENTUM obesity trial (391 subjects, 48 weeks), and the Phase 2b IMPACT trial in biopsy-confirmed MASH (NCT05989711, 212 subjects) [1, 7, 8, 9, 10]. Extension to 24 weeks produced 75.2 percent liver fat reduction at 1.8 mg and 6.2 percent body weight reduction versus placebo [7]. In the Phase 2b IMPACT trial (Noureddin et al. 2025) in 212 patients with biopsy-confirmed MASH and fibrosis stages F2 or F3, pemvidutide met the primary endpoint of MASH resolution without fibrosis worsening: 59.1 percent at 1.2 mg and 52.1 percent at 1.8 mg versus 19.1 percent for placebo (p < 0.0001 for both comparisons) [11]. Topline 48-week data demonstrated continued antifibrotic activity with statistically significant improvements in Enhanced Liver Fibrosis score and liver stiffness measurement versus placebo [12]. The United States Food and Drug Administration has granted Breakthrough Therapy Designation for pemvidutide in MASH (January 2026) and Fast Track designations for both MASH and AUD [13, 14]. Phase 3 registrational programs for MASH and the VELOCITY Phase 3 program for obesity are in planning as of May 2026. Safety across completed trials has been favorable; adverse events are predominantly gastrointestinal (nausea, diarrhea, decreased appetite), mild to moderate in severity, and concentrated in the first 16 weeks of treatment. No imbalances in cardiac events, arrhythmias, or clinically meaningful heart rate increases have been observed. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.